Mumbai: Wockhardt will now be able to market the full range of its potent antibiotic injection, Ceftriaxone, in America as it has received the US FDA approval for three more strengths of the said drug.
The Ceftriaxone range would be marketed by the company’s US subsidiary Wockhardt USA Inc, through various hospitals, wholesalers, doctor clinics and managed care companies in the US, Wockhardt informed the Bombay Stock Exchange.
The new approval is for three more strengths — 250 mg, 500 mg and 2 gm. The company already markets Ceftriaxone 1 gm injection.
“This is the fourth ANDA approval in four weeks and our sixth injection product in the US market,” Wockhardt Chairman Habil Khorakiwala said adding that, “We are launching three injection products in the US this week — Furosemide diuretic, Ketorolac anti-inflammatory and Ceftriaxone antibiotic.”
Ceftriaxone is the generic name for Rocephin sold by Roche.
It is one of the most widely used antibiotics in hospitals all over the world for treating various kinds of bacterial infection, bone and joint infection, meningitis, abdominal, skin and urinary tract injections.
The US consumes over 25 million vials worth $200 million a year as per IMS. It is currently Wockhardt’s third largest market after Europe and India.
With three more products to be added this week, the company would have 20 products in the US.